Characteristics | Controls (n = 50) | ME/CFS (n = 50) | Total (n = 100) | ||||||
---|---|---|---|---|---|---|---|---|---|
Females | Males | Females | Males | Females | Males | ||||
Sex (n) | 25 (50%) | 25 (50%) | 25 (50%) | 25 (50%) | 50 (50%) | 50 (50%) | |||
Age (Mean \( \mp \)SD) | 44.7 (12.2) | 34.5 (9.7) | 48.4 (9.9) | 38.7 (12.9) | 46.6 (11.2) | 36.6 (11.5) | |||
BMI \( \mp \) (Mean \( \mp \) SD) | 27.2 (2.8) | 27.4 (3.6) | 26.9 (4.9) | 26.2 (4.7) | 27.0 (4.0) | 26.8 (4.2) | |||
Race/ethnicity | |||||||||
 Caucasian (n) | 17 (34%) | 18 (36%) | 23 (46%) | 20 (40%) | 40 (40%) | 38 (38%) | |||
 Non-caucasian (n) | 8 (16%) | 7 (14%) | 2 (4%) | 5 (10%) | 10 (20%) | 12 (24%) | |||
Symptoms | |||||||||
 Fatigue (n) | 0 | 1 (2%) | 21 (42%)*** | 23 (46%)*** | 21 (21%) | 24 (24%) | |||
 Physical pain (n) | 2 (4%) | 8 (16%) | 24 (48%)*** | 18 (36%)*** | 26 (26%) | 26 (26%) | |||
 Headache (n) | 2 (4%) | 0 | 18 (36%)*** | 14 (34%)*** | 20 (20%) | 14 (14%) | |||
 Cognitive difficulties (n) | 0 | 1 (2%) | 17 (34%)*** | 23 (46%)*** | 17 (17%) | 24 (24%) | |||
Supplement | |||||||||
 DHA (n) | 1 (2%) | 1 (2%) | 5 (10%) | 3 (6%) | 6 (6%) | 4 (4%) |